Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 2,104 of 2,219.
    «« First « Previous 2100  2101  2102  2103  2104  2105  2106  2107  2108  Next» Last»»
    EudraCT Number: 2022-002860-59 Sponsor Protocol Number: ISEE2009 Start Date*: 2022-12-08
    Sponsor Name:IVERIC bio, Inc.
    Full Title: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Co...
    Medical condition: geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003797-10 Sponsor Protocol Number: APL2-ALS-206 Start Date*: 2021-04-06
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000964-27 Sponsor Protocol Number: WP2018 Start Date*: 2018-05-09
    Sponsor Name:Karolinska Institutet
    Full Title: Medical termination of pregnancy from day 85 to day 153 of gestation: A randomized comparison between administration of the initial dose of misoprostol at home or in the clinic
    Medical condition: Unwanted pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002769-44 Sponsor Protocol Number: ESAP Start Date*: 2015-09-28
    Sponsor Name:Medical University of Graz
    Full Title: Efficacy and safety of an accelerated outpatient protocol for hymenoptera venom immunotherapy
    Medical condition: Immunotherapy against systemic anaphylactic sting reactions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10001749 Allergy to sting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002338-29 Sponsor Protocol Number: ACE-MM-102 Start Date*: 2015-06-22
    Sponsor Name:Acetylon Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in ...
    Medical condition: The treatment of multiple myeloma (MM) patients who have received at least 2 prior therapies, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to the most rece...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004217-24 Sponsor Protocol Number: s58396 Start Date*: 2015-11-30
    Sponsor Name:UZ Leuven
    Full Title: Pharmacokinetic study of paracetamol in patients over 80 years old admitted to an acute geriatric ward
    Medical condition: Pyrexia Pain
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004730-11 Sponsor Protocol Number: KMT2021001 Start Date*: 2022-02-18
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective, controlled, single-arm pilot study on treosulfan, fludarabine, and cyclophosphamide (TreoFC) as conditioning treatment before haploidentical hematopoietic stem cell transplantation f...
    Medical condition: Conditioning therapy before haploidentical hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003370-41 Sponsor Protocol Number: VAT00002 Start Date*: 2021-08-23
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001653-27 Sponsor Protocol Number: MarsyasII Start Date*: 2019-12-20
    Sponsor Name:Aposcience AG
    Full Title: A randomized, placebo-controlled, double-blind study to evaluate safety and dose dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II)
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001229-26 Sponsor Protocol Number: ALXN2050-MG-201 Start Date*: 2021-12-21
    Sponsor Name:ALEXION PHARMACEUTICALS INCORPORATED
    Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003019-24 Sponsor Protocol Number: 80-87200-98-1017 Start Date*: 2021-08-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Effectiveness of analgesic ear drops as add-on treatment to oral analgesics in children with acute otitis media: a pragmatic randomised controlled trial
    Medical condition: Acute otitis media
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003880-38 Sponsor Protocol Number: 270-201 Start Date*: 2015-06-01
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Patients with Severe Haemophilia A
    Medical condition: Haemophilia A
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006003-42 Sponsor Protocol Number: ENFORCE Start Date*: 2020-12-30
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE)
    Medical condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoi...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2023-001026-34 Sponsor Protocol Number: CSL627_3003 Start Date*: 2024-12-19
    Sponsor Name:CSL Behring
    Full Title: A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) with Hem...
    Medical condition: Congenital Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-004637-20 Sponsor Protocol Number: D361DC00001 Start Date*: 2021-07-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6i and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Rec...
    Medical condition: Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005225-81 Sponsor Protocol Number: VALYM Start Date*: 2021-04-28
    Sponsor Name:LYSARC
    Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004721-23 Sponsor Protocol Number: 20190135 Start Date*: 2022-01-28
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
    Medical condition: Advanced Solid Tumors with KRAS p.G12C Mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005114-18 Sponsor Protocol Number: MK-1308A-008 Start Date*: 2021-07-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-...
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079619 MSI-high LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004892-41 Sponsor Protocol Number: VT-001-0050 Start Date*: 2021-07-13
    Sponsor Name:Vera Therapeutics, Inc.
    Full Title: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2100  2101  2102  2103  2104  2105  2106  2107  2108  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 13:57:08 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA